Jubilant Pharmova Ltd. benchmarking: Performance to industry peers

Financial

	Jubilant Pharmova	Caplin Point Lab	Alembic Pharma
Operational Metrics
Pharmaceuticals
Australia DMF fillings	14.0 .	n/a	n/a
Number of ANDA's Filed in Europe	38.0	n/a	21.0
Number of ANDA's Approved in Europe	37.0	n/a	19.0
Number of ANDA's Filed in Canada	24.0	n/a	21.0
Number of ANDA's Approved by Canada	24.0	n/a	20.0
Number of ANDA's Filed in USA	100.0 .	64.0 .	270.0 .
Number of ANDA's Approved By USFDA	62.0 .	55.0 .	232.0 .
US DMF Filings	98.0 .	n/a	143.0 .
Canada DMF fillings	42.0 .	n/a	n/a
Japan DMF Filings	15.0 .	n/a	n/a
R&D as a % of Total Sales	0.18 %	3.78 %	9.0 %
Financials
5 yr Average ROE	8.05 %	19.84 %	12.89 %
5yr average Equity Multiplier	1.96	1.15	1.39
5yr Average Asset Turnover Ratio	0.61	0.68	0.86
5yr Avg Net Profit Margin	6.45 %	25.35 %	11.15 %
Price to Book	1.95	4.06	2.61
P/E	29.78	20.9	22.09
5yr Avg Cash Conversion Cycle	-39.98 Days	70.68 Days	9.46 Days
Inventory Days	74.06 Days	66.07 Days	99.1 Days
Days Receivable	45.59 Days	110.7 Days	66.32 Days
Days Payable	149.89 Days	85.23 Days	164.9 Days
5yr Average Interest Coverage Ratio	3.78	633.04	30.59
5yr Avg ROCE	8.15 %	24.45 %	15.26 %
5yr Avg Operating Profit Margin	16.76 %	31.52 %	17.29 %
5 yr average Debt to Equity	0.55	0.0	0.14
5yr CAGR Net Profit	0.08 %	17.23 %	-12.64 %
5yr Average Return on Assets	4.12 %	17.23 %	9.32 %
Shareholdings
Promoter Holding	47.68 %	70.57 %	69.74 %
Share Pledged by Promoters	5.4 %	0.0	0.0
Change in Promoter Holding (3 Yrs)	-3.0 %	1.77 %	0.13 %
Change in Mutual Fund Holding (3 Yrs)	7.29 %	0.93 %	2.35 %

Business

	Jubilant Pharmova	Caplin Point Lab	Alembic Pharma
Product Wise Break-Up	Product Wise Break-Up Radiopharmaceuticals 46.89 Contract Manufacturing 17.66 Anti-allergic 9.75 Solid dosage formulations 8.71 Active Pharmaceutical Ingredient (API) 7.91 Contract Research and Development Services 7.87 India branded pharmaceuticals 0.7 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 Branded Generic 0 Generic 0 Formulations 0 API 0 Others 0.51	Product Wise Break-Up Branded Generics 25.0 Radiopharmaceuticals 0 Contract Manufacturing 0 Nutritional products 0 Formulations 75.0 Specialty intermediates 0 Solid dosage formulations 0 India branded pharmaceuticals 0 Life science chemicals 0 Active Pharmaceutical Ingredient (API) 0 Formulations 0 Anti-allergic 0 0 API 0	Product Wise Break-Up Branded Generic 0 Radiopharmaceuticals 0 Contract Manufacturing 0 Nutritional products 0 Generic 0 Specialty intermediates 0 Solid dosage formulations 0 India branded pharmaceuticals 0 Life science chemicals 0 Active Pharmaceutical Ingredient (API) 0 Formulations 85.93 Anti-allergic 0 0 Active Pharmaceutical Ingredient (API) 14.07
Segment Break-Up	Segment Break-Up Radiopharma 45.26 CDMO Sterile Injectables 20.76 Drug discovery and development solutions 15.77 Allergy Immunotherapy 9.79 Generics 8.43 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0	-	-
Location Wise Break-Up	Location Wise Break-Up Americas and Europe 91.35 Rest of the World 5.89 India 2.76 China 0 USA 0 Africa 0 LATAM 0	Location Wise Break-Up USA 18.0 Latin America 76.0 Rest of the World 0 China 0 Americas and Europe 0 India 0 Africa 6.0	Location Wise Break-Up USA 0 LATAM 0 Rest of the World 60.76 China 0 Americas and Europe 0 India 39.24 Africa 0
Operating Profit Break-Up	Operating Profit Break-Up Radiopharma 35.32 Allergy Immunotherapy 27.7 CDMO Sterile Injectables 26.26 Contract Research and Development 10.72 Generics 0 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0	-	-
Capex	Capex CDMO 75.99 Radiopharma 15.19 Contract Research and Development 5.98 Proprietary Novel Drugs 1.46 Generics 0.65 Allergy Immunotherapy 0.63 Life Science Ingredients 0 Others 0.1	-	-
Asset Break-Up	Asset Break-Up Contract Research and Development 12.97 Proprietary Novel Drugs 2.17 Life Science Ingredients 0 Pharmaceuticals 0 Others 84.86	-	-

Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd.

Financial

Business

SIGN UP FOR FREE